The Mystery Solved: Why Magic Mushrooms Turn Blue

Why do magic mushrooms turn blue when they are cut? Chemists have now unravelled this decade-old mystery, in the process revealing that the dark blue pigments at the centre of the mystery are similar to indigo, the dye used to produce blue jeans.

Magic mushrooms or Psilocybe are fungi producing the psychotropic compounds psilocybin and psilocin. They are one of several species that instantly develop a blue coloration when they are cut or bruised. In Boletales mushrooms, oxidised gyrocyanin or pulvinic acid are the source of the blue colour. But that isn’t the case in Psilocybe mushrooms.

Previous research had established that the blue colour was caused by oxidised psilocybin, but the nature of the pigment and the biochemical pathway producing it had remained elusive.

An image showing the chemical structures of psilocybin and psilocin

Magic mushrooms contain a number of psychotropic compounds including psilocybin and psilocin.

Dirk Hoffmeister from the Leibniz Institute for Natural Product Research and Infection Biology, Germany and his team had been working with Psilocybe cubensis for several years. Growing the mushrooms in their lab, they had seen the mysterious blueing reaction countless times. ‘We were just curious and tried to solve a phenomenon that’s been known for decades,’ Hoffmeister says.

But when they tried to extract and purify the blue compound, they failed. ‘It puzzled and challenged us,’ says Hoffmeister. ‘This is where previous researchers – very talented people – had to give up, and that’s where we went one step further with unconventional analytical methods.’

The researchers dug deep into the analytical toolbox with liquid chromatography–mass spectrometry, Maldi mass spectrometry, infrared spectroscopy, as well as time-resolved nuclear magnetic resonance spectroscopy to observe the compounds as they form.

The pigment, as it turns out, is not just a single compound but a complex mixture of linked psilocybin oxidation products. Most of them are quinoid psilocyl oligomers – compounds not unlike indigo, a deep blue pigment used to dye jeans. ‘[The blue compounds and indigo] share structural similarities in the indole core, and in both the basis for the colour is a quinoid,’ says the study’s lead author Claudius Lenz.

All of the six mushroom pigments the team identified are products of a cascade reaction starting with psilocybin. A phosphatase enzyme takes off its phosphate group, converting it into psilocin. An oxidising laccase then creates psilocyl radicals, which combine to form C-5 coupled subunits and then further polymerise via C-7. ‘I think they did a beautiful job of showing the cascade reaction,’ says Jaclyn Winter, who studies natural product biosynthesis in bacteria and fungi at the University of Utah, US.

A scheme showing the blueing reaction in P cubensis, catalyzed by PsiP and PsiL

Source: © 2019 Claudius Lenz et al

Proposed reaction scheme for the conversion of psilocybin into blue pigments

What exactly the blue pigments do, however, remains a mystery. ‘Our hypothesis – and we don’t have any evidence for this yet – is that it might serve a protective role, like an on-demand repellent against predators,’ says Hoffmeister. The compounds might produce reactive oxygen species, which are toxic to any insect nibbling on the mushrooms. ‘I think we’re going to see a lot of follow-up studies on the true ecological role of these molecules,’ Winter says.

Hoffmeister hopes that his study not only inspires others to study fungi from a chemistry perspective but also changes people’s mind about psilocybin. ‘Psilocybin is looked at as this illegal, recreational drug, but it has a fantastic potential as a medication for therapy resistant depression,’ he says.

Winter agrees. ‘There’s quite a few groups who are studying psilocybin, and especially because it’s been legalised in the US in various states, and because it’s in clinical trials,’ she says. ‘I think [this study] is going to have a huge impact in the field.’

Magic Mushrooms vs Pharmaceuticals in Treating Depression

Hey Shroomfam!

We’ve previously covered in-depth some of the research that has been conducted regarding the potential efficacy of magic mushrooms in the treatment of depression. You can read our article for a bit of the background, but the gist of it is this: psilocybin (the psychoactive component found in magic mushrooms) has repeatedly been shown to be helpful in treating depression, along with a host of other mental illnesses.

What has been lacking for some time, however, is comparative research looking into how well psilocybin therapy can work compared with more traditional methods of psychological treatment. However, a study recently published by The New England Journal of Medicine provided some preliminary insight into just that – we read the study, and prepared an article here to help summarize its goals and findings for you!

The purpose of this study more specifically was to compare the efficacy of psilocybin and escitalopram in the treatment of depression. Before diving into the comparison, let’s talk a little bit about escitalopram.

Escitalopram Background

Escitalopram (frequently sold under the brand names of Cipralex and Lexapro,) is an SSRI (selective serotonin reuptake inhibitor) antidepressant. Many patients suffering from the symptoms of depression exhibit signs of serotonin imbalance. Serotonin is a very complex neurotransmitter that is naturally produced by the human body. We could write an entire series about this chemical, its role in the human body, and the research that has been done around it – but for now, the important thing to know is that serotonin is synthesized in the central nervous system, and some of its functions include the regulation of mood, appetite, and sleep as well as some cognitive functions such as memory and learning.

People suffering from depression often exhibit lower-than-average levels of serotonin production, and so drugs like Escitalopram were developed to help these patients regulate levels of serotonin production, and alleviate some of the symptoms of depression (and potentially even cure it!)

Psilocybin and Serotonin

Sounds pretty helpful, right? So where does psilocybin fit into this, and what does it have to do with serotonin? Well, there’s a little journey to follow there as well. When magic mushrooms are ingested, psilocybin is metastasized into a sister chemical called psilocin. Once processed, the psilocin is believed to stimulate serotonin receptors in the brain – effectively mimicking the body’s naturally occurring serotonin. With the oversight of a trained medical professional, psilocybin has been used as a more natural alternative to manufactured drugs with the aim of balancing serotonin levels in the human body.

In another word, doctors have been experimenting with using shrooms instead of meds to help regulate levels of serotonin in depressive patients. It has been effective, but thus far there has been little research done to compare just how effective it is compared with pharmaceuticals.

Okay, so I think that’s enough of a background for us to go on. So, let’s talk about the study itself.

The Methods of the Study

The study was conducted as a double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive order. Psilocybin was compared with escitalopram over a 6-week period; patients were assigned in 1:1 ratio, and received comparable doses of both drugs depending on the group they were assigned to. In the end, the patients were re-assessed on their depressive symptoms to compare the efficacy of both courses of treatment. The changes are measured via a Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16) – and differences in their scores on those reports before and after treatment.

In laymen’s terms, people were scored on their levels of depression, randomly sorted into two groups, given one drug or the other without knowing which was which, and the results were studied at the end. At the end of the trial, their level of depression was tested again.

Results of the Study

Of the 59 patients in the study, 30 were given psilocybin and 29 escitalopram. The QIDS-SR-16 is scored from 0 to 27, with a higher number indicating a greater level of depression. After the trial was completed, patients in the psilocybin group saw their QIDS-SR-16 scores drop by an average of 8 points, while patients in the escitalopram group saw their scores drop by only 6 points. Although both treatments were observed to be effective, it’s notable that the psilocybin group saw, on average, a reduction in levels of depression over 30% greater than those in the escitalopram group

Additionally, secondary endpoints were studied, evaluating the work, social functioning, anxiety, and general wellbeing of patients in both groups. Similar patterns favouring psilocybin were found in these trials as well.

Conclusions of the Study

Although it is tempting for any advocate of psychoactive medicine to point to the results of this trial as conclusive proof of the superiority of psilocybin to pharmaceuticals, the reality is that these results are far from conclusive.

Medical research is slow work – and it has, over the past couple of decades, been especially slow regarding psilocybin therapy owing to the illegal status of the drug in most first-world countries. However, that trend is shifting – and more and more money is being poured into psilocybin research every day, with research continuously coming back in support of this amazing drug. 

At the end of the day, this was a small trial conducted over a short period with a small number of patients. Before any kind of definite conclusion can be reached, there is much more clinical research that needs to be done. George Goldsmith, CEO, and Co-founder of Compass Pathways, a psilocybin-focused research group working on discovering new therapies for the treatment of depression, had this to say:

“In a field of research where it is very difficult to separate treatments in head-to-head comparative efficacy trials, this study found signals favouring psilocybin therapy over escitalopram. This is an encouraging investigator-initiated study that supports the need for additional clinical investigations in larger, well-powered studies to more accurately determine the efficacy of psilocybin in treating major depressive disorder.”

Parting Thoughts

The evidence of the incredible healing and restorative properties of psilocybin mushrooms continues to mount each day. However, this is a relatively new frontier of scientific research and something about which we are only beginning to scratch the surface.

We want to emphasize that the writer of this article is not a medical professional – and if you think you are suffering from the symptoms of depression or any other mental illness, we recommend speaking with a trained medical professional to seek treatment.

However, those looking to buy shrooms online can find many places to do so!

 

Canada’s First Psychedelic Therapy Training Program

There is some amazing news for mental health professionals in Canada who are interested in learning more about psychedelic-assisted therapy and receiving dedicated instruction on and insight into how psychedelic medicines can be leveraged as they become legally accessible across Canada.

Back in February, the ATMA Journeys Centers in Calgary, AB announced their Psychedelic Therapy Training Program for Mental Health Professionals program – providing Canadian mental health professionals for the first time with access to top-tier training in magic mushroom therapy. The initiative was launched with the full blessing of the Federal and Provincial governments, in conjunction with the Wayfound Mental Health Group, Inc. and the Psychologists Association of Alberta.

The course was massively popular, selling out in a matter of days, and now boasts a substantial waiting list as rave reviews have come pouring in after the first 3-month cohort concluded.

About ATMA Journeys Centers

ATMA Journey Centers is a clinic founded by Dr. David Harder and Dr. Vu Tran in Calgary, AB. ATMA is dedicated to advancing accessibility to psychedelic therapy in Canada. On their website, they claim that they “believe that psychedelics hold the key to actually resolving the root causes of mental health issues that affect so many.” Their self-stated mission is “to deliver effective and innovative healing and transformative experiences that awaken the inner healer and allow a deeper connection with self and with the world.”

About The Wayfound Mental Health Group

The Wayfound Mental Health Group was founded in Calgary, AB over 21 years ago by Dr. William McElheran. McElheran has been widely regarded as a pioneer at the cutting edge of the most effective emerging techniques in trauma treatment, and this reputation has attracted some of the best counseling talent in the world to his clinic. The partnership with ATMA represents their first official foray into the world of psychiatric therapy.

About The Program

It is unsurprising that the demand for mental health therapists has shot up dramatically over the course of the COVID-19 pandemic. Rising unemployment, concerns about health, and increasingly isolated lifestyles are suspected to contribute to this unprecedented level of demand.

David Harder, Co-CEO of ATMA says, “we’re seeing substantial interest from therapists who are looking for more effective tools to help their clients. Significant evidence-based research around psychedelic medicine continues to emerge which is highlighting how promising psychedelic medicine is. There appears to be a shift in the industry where therapists have heard about the potential of psychedelic medicine and are now stepping forward to learn about it.”

ATMA and Wayfound saw a gap in the increasing demand from Canadian patients and the availability of training for mental health professionals in this same area. Harder commented,

“One of the major obstacles in increasing access to psychedelic therapy is an acute shortage of therapists who have the education, knowledge, and resources both from a psychological and psychedelic perspective to provide the necessary support and guidance to patients. This training program provides an accredited base of understanding for therapists who are seeking information and therapy involving psychedelics.”

Consulting with leading authorities on psychedelic therapy from all over the world, this course consolidates their teachings to help address that problem, and provide Canada’s most forward-thinking therapists with access to top-of-the-line training in therapy with magic mushrooms in Canada.

On the importance of training mental health professionals on how to properly apply psychedelic therapy in their own practices, Megan McElheran, CEO of Wayfound said:

“Research has shown that psychologists are uniquely skilled to support the psychedelic process, and the psychotherapeutic process is proven to be an essential component to the success of psychedelic treatment. For this reason, I support psychologists and other health care providers to build their capacity and skills through training that prioritizes professional, clinically-sound, ethical practice and due diligence in the delivery of care.”

With psychedelics increasingly entering into the mainstream of the media, more and more people looking for access to magic mushrooms in Calgary, and all signs pointing to rapidly impending legalization in Canada, Vu Tran emphasizes the importance of trained therapists in helping guide psychedelic therapy. He commented,

“The training program is just the first step of our plan to create solutions for the industry to scale and support therapists who wish to participate in psychedelic-assisted therapy…. We want to see more therapists educated on the benefits of psychedelic therapy in hopes that more awareness will help the legislative and policy frameworks move forward in a timely manner. Mental health professionals will face great challenges with capacity in the coming years, so we’re working towards a support structure for therapists to progressively look at psychedelic therapy as a growing part of their business without a steep learning curve. Psychedelics have the proven ability to reduce lifelong ongoing patient therapy, and this can assist in reducing the burden on the health care system.”

Rave Reviews

The first cohort of the month-long program concluded in May, and the 2nd sold-out cohort began in June of this year. One of the therapists who graduated from the first training, Dr. Angela Grace, had this to say:

“The training program provides an excellent overview of psychedelic therapy with experienced practitioners and researchers in the field. The learning, discussions, experiences, and connections made are invaluable as an introduction to the field.”

Information on Upcoming Programs

According to ATMA and Wayfound, the feedback has been immensely positive across the board. So much so that they immediately launched a second training, and have three more planned for later this year, on September 7, October 5, and November 2.

David Harder comments: “We encourage any mental health professional to contact us to discuss the training programs. This emerging field is a significant opportunity for licensed therapists who want to add another effective tool to their practice and learn how psychedelics can integrate into an existing practice.”

You can learn more about the program, and apply here!

The Ultimate Playlist for Magic Mushroom Therapy

There are many wonderful ways to use magic mushrooms, but more and more everywhere you look, you are reading about the incredibly beneficial therapeutic applications of shrooms. One of the institutions leading the way in this research is The Johns Hopkins Center for Psychedelic and Consciousness Research, out of Johns Hopkins University in Baltimore, MD. Since 2000, and backed by tens of millions of dollars in funding, Johns Hopkins was the first clinical center given regulatory approval in the United States for conducting clinical research using psychedelics as therapeutic aids.

Since that time, they have remained at the forefront of psychedelic research and clinical advancements, demonstrating how magic mushrooms can be effectively used to help in the treatment of depression, anxiety, post-traumatic stress disorder, and many other mental health conditions.

Of course, not everyone can make the trip to Baltimore to receive their patented brand of psychedelic therapy – but we’ve done a little bit of digging to uncover some tools you can use right in your own home.

Namely, their Psilocybin Research Sacred Knowledge playlist – which has been added to Spotify, and we are sharing with you here!

This playlist is 7 hours and 40 minutes in length, and its beautiful progression of concertos, baïlèros, and symphonies has been painstakingly and thoughtfully tweaked over decades of research into psychedelic medicine. The playlist is designed to help carry patients through every stage of the psilocybin session. The music starts simple and relaxing, increasing in complexity and intensity over time as it guides the patient from the beginning of their session, through ingesting the medicine, to beginning to climb and hitting the peak, and the eventual coming down.

The History of the Playlist

The playlist is the brainchild of psychologist Bill Richards, who has been involved in psychedelic research since the early 1960s. As one of the leading researchers at the Johns Hopkins Center, he has this to say about the effects this playlist can have on those who listen to it during their trip:

“We’re exploring the human psyche, which might take you through some painful things in childhood. It may take you into some archetypal or visionary realms that you never knew were possible. It might take you beyond usual consciousness into a realm that feels eternal.

The music chromatically develops, and it goes up and reaches this exquisite climax and then comes back down… It’s going somewhere, it’s picking you up and carrying you. It’s got some force, some substance. It doesn’t have very unpredictable changes of rhythm or something that’s going to startle or frighten you. So, it’s a net of reassurance, almost, and of leadership.”

The music helps keep participants from prematurely returning to normal conscious awareness, Richards says.

“I think of it as a nonverbal support system, sort of like the net for a trapeze artist,” he says. “If all is going well, you’re not even aware that the net is there — you don’t even hear the music — but if you start getting anxious, or if you need it, it’s immediately there to provide structure.”

Recently, the playlist was featured prominently and supported the experiences of all those who participated in a new study published by Johns Hopkins on Nov 4, which found that psychedelic substances can have profoundly beneficial effects on those suffering from Major Depressive Disorder.

How to Use the Playlist

The best way to use the playlist is as follows:

The first 30 minutes of the playlist are designed to help set the patient up for the impending psychedelic experience. So, you should start the playlist before taking the mushrooms, somewhere where you can be relaxed, with your eyes closed, in meditation, or a state of deep relaxation. This time should be spent on what we call intention-setting: becoming clear with yourself on what the purposes of this session are, and what you want to get out of it.

It is important in the use of mushrooms for therapy not to skip this step. We must be clear with ourselves in what we want to get out of the experience – this will help shape the course of our trip, and help keep us grounded in the psychedelic journey that is to follow.

Once you feel that your intentions are clear, it’s time to dose yourself. The playlist is designed to support a more moderate to heavy usage. Depending on your tolerance, somewhere from 2.5 to 4 grams should be appropriate. Once the mushrooms have been ingested, lie back again and close your eyes – try not to focus too hard on the music, but rather lean into it as a guide that will help guide your mind through the trip to come.

Your mind may wander to different subjects, but you would do best to keep your intention in mind. If negative thoughts or feelings arise, you shouldn’t try to run from them or shut them down, but allow them to wash over you as you relax further into the playlist. About 85 minutes in, the playlist begins to seriously increase in its complexity and intensity, as you approach your peak. Follow the trip – go where it wants to take you, and allow the music to be your tether to the world.

The songs contain no English lyrics at all (and few lyrics in general) during the first 6 hours of the playlist. This is on purpose so the music will not provide any kind of distraction from the important work that’s happening inside your mind, but rather serve as a guide. Says Richards,

“I think of it as a nonverbal support system, sort of like the net for a trapeze artist, if all is going well, you’re not even aware that the net is there — you don’t even hear the music — but if you start getting anxious, or if you need it, it’s immediately there to provide structure.”

As the playlist winds down, you will begin to hear some more recognizable songs with recognizable lyrics, designed to help you transition smoothly back to reality.

In closing, Bill Richards had this to say about the playlist and how it affected his patients:

“It spoke [to them]. It took on meaning in the struggle, the unfolding, the dissonance being resolved. They could understand that that type of classical music is a language about life and human experience. And when you’re in the music, it’s so different from listening to the music.”

If you’re interested in reading more about the story, you can check out this article on the Johns Hopkins website!

Phone screen Phone screen Phone screen Phone screen